The Filing Desk

Claritev

CTEV · NYSE · Health Care · Financials, fiscal 2018 to 2025

CTEV · Last close · November 19, 2026
$19.03
Value Claritev yourself

Claritev's revenue rose 3.7% to $965 million in fiscal 2025. Its operating margin was 3.0%, up from −149.3% a year earlier. Free cash flow was −$12 million. The diluted share count rose 1.8%.

CLARITEV CORPORATION Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001793229-26-000017 Updated
Revenue
$965M
3.7%
Operating margin
3.0%
152.3 pts
Net income
−$284M
 
Free cash flow
−$12M
 
Return on capital
0.5%
20.7 pts
Market cap
$324M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-40), so every year is on today's share basis. Return on equity for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Claritev does

Claritev, formerly known as MultiPlan, is a technology, data and analytics company that works on healthcare costs and billing. It sells its services mainly to health insurers and other payers, employers that fund health plans, and the plan members and providers connected to them. It was founded in 1980.

Its main services help payers manage the cost of out-of-network claims, which are bills from doctors and hospitals outside a plan's network, and check that both in-network and out-of-network claims are billed and paid correctly. It often does this before the claim is paid. A portion of the revenue from its claims intelligence solutions is based on a percentage of the price concessions from providers on claims of its payer clients.

The company has also entered new areas, including payer risk analytics and network transparency and analytic services. It says it has put over $500 million into capitalized software development in the past five years, and it is pursuing a plan it calls Vision 2030.

Its biggest risks, as it describes them

  • Losing key clients or depending on a core group of clients for much of its revenue.
  • Failing to gain the benefits it expects from its Vision 2030 plan or from entering new lines of business.
  • Not having enough cash or liquidity to run the business and meet its obligations.
  • Competition and pricing pressure in a fragmented market.
  • Changes in the healthcare industry, and legal claims it may face.
From Claritev's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2018 to 2021, earnings per share grew 21.1% a year and net income 41.3% a year, as new shares raised the share count by 57% and diluted each share's earnings. Claritev then lost money in fiscal 2022, 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments185334721717
Debt incl. finance leases4,9724,8224,6004,5664,612
Net debt (negative means net cash)4,7864,4884,5284,5494,595
Net debt to EBITDA6.0x96.4x7.8x—9.7x
Debt to equity2.1x2.7x2.7x——
Interest coverage1.4x−1.2x0.5x−4.3x0.1x
Current ratio2.2x2.5x1.2x0.8x0.9x
Quick ratio2.2x2.5x1.2x0.8x0.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Claritev's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 6 insiders bought $1.9 million of Claritev shares on the open market, and 3 insiders sold $919,352, $276,055 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 21, 2026Douglas Michael GarisEvp&cfoSold plan9,025$30.59$276,055Form 4
Aug 28, 2026Travis DaltonPres., CEO & Executive Chair, DirectorBought1,950$38.48$75,036Form 4
Aug 27, 2026Travis DaltonPres., CEO & Executive Chair, DirectorBought4,500$38.81$174,645Form 4
Aug 14, 2026Tiffani MisencikSVP, Chief Growth OfficerSold8,850$40.07$354,620Form 4
Aug 10, 2026William B. MintzSVP, Chief Strategy OfficerSold8,431$34.24$288,677Form 4
Jun 9, 2026Nutter CarolSVP, Chief People OfficerBought875$28.41$24,859Form 4
May 19, 2026John Michael PrinceDirectorBought10,000$16.00$160,000Form 4
May 18, 2026Travis DaltonPres., CEO & Executive Chair, DirectorBought20,920$12.36$258,638Form 4
May 18, 2026Michael KimEVP, Chief Digital OfficerBought3,000$16.65$49,950Form 4
Mar 16, 2026Douglas Michael GarisEvp&cfoBought1,300$17.69$22,997Form 4
Mar 12, 2026Michael KimEVP, Chief Digital OfficerBought15,000$16.50$247,500Form 4
Mar 2, 2026Tara O'NeilSVP, General CounselBought750$12.99$9,742Form 4
The latest 12 of 15 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 83 of 85 of 8
Rule of 40−4.4%−4.3%2.5%
Altman Z''0.29−3.20−1.66
Accruals ratio−3.7%−28.9%−8.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassPassPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score3 of 83 of 85 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Claritev side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
ClaritevFY253.7%3.0%−1.3%0.5%9.7x5
WaystarFY2516.5%22.7%25.8%3.5%3.6x5Compare
GoodRxFY250.6%11.0%20.6%5.8%1.4x6Compare
OmnicellFY256.5%0.4%7.3%0.2%−0.3x6Compare
DoximityFY2613.1%33.3%50.6%91.3%−3.3x4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1,0419839381,1181,080962931965
Revenue growth—−5.6%−4.6%19.2%−3.4%−10.9%−3.2%3.7%
Gross profit————————
Research and development————————
Operating income428368−132386−363162−1,39029
Net income3610−521102−573−92−1,646−284
Diluted EPS (US$)3.600.80−44.406.40−36.00−5.69−101.92−17.30
Diluted shares (millions)1010121616161616
Cash flow
Cash from operations292284377405372172108117
Capital expenditure6466718590109118130
Free cash flow22921830732028363−11−12
Dividends paid00000000
Share buybacks00101100015100
Acquisitions0014000005
Stock-based compensation5−154061817182728
Balance sheet at fiscal year end
Cash and short-term investments522127185334721717
Debt incl. finance leases—5,3974,5784,9724,8224,6004,5664,612
Total assets—8,3608,2848,2207,3716,9655,1514,888
Total liabilities—6,3755,7265,8765,5815,2565,0675,056
Shareholders' equity1,9901,9852,5582,3451,7901,70984−174
Margins and ratios
Gross margin————————
Operating margin41.1%37.5%−14.1%34.5%−33.6%16.9%−149.3%3.0%
Net margin3.5%1.0%−55.5%9.1%−53.1%−9.5%−176.8%−29.4%
Free cash flow margin22.0%22.2%32.7%28.6%26.2%6.5%−1.1%−1.3%
Rule of 40 (growth + FCF margin)—16.6%28.1%47.8%22.8%−4.4%−4.3%2.5%
Return on capital——−1.4%4.1%−4.3%2.0%−20.2%0.5%
Return on equity——−22.9%4.2%−27.7%−5.2%−183.6%—
Return on assets——−6.3%1.2%−7.3%−1.3%−27.2%−5.7%
Net debt to EBITDA—7.1x16.9x6.0x96.4x7.8x—9.7x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Claritev's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Claritev.